Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) EVP Linda Burkly sold 11,886 shares of Editas Medicine stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $5.42, for a total value of $64,422.12. Following the transaction, the executive vice president now owns 73,136 shares of the company’s stock, valued at approximately $396,397.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Editas Medicine Stock Performance
EDIT opened at $5.65 on Monday. The stock has a market cap of $464.66 million, a price-to-earnings ratio of -2.69 and a beta of 2.01. The firm’s fifty day moving average is $5.26 and its 200 day moving average is $6.59. Editas Medicine, Inc. has a fifty-two week low of $4.45 and a fifty-two week high of $11.69.
Editas Medicine (NASDAQ:EDIT – Get Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.13). Editas Medicine had a negative return on equity of 47.34% and a negative net margin of 239.36%. The firm had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $11.14 million. During the same period last year, the company earned ($0.71) earnings per share. The firm’s revenue was down 88.9% on a year-over-year basis. On average, equities research analysts predict that Editas Medicine, Inc. will post -2.7 earnings per share for the current year.
Institutional Trading of Editas Medicine
Wall Street Analysts Forecast Growth
EDIT has been the subject of several analyst reports. Barclays reduced their price target on Editas Medicine from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Thursday, May 9th. StockNews.com lowered shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Thursday, May 9th. Citigroup dropped their target price on shares of Editas Medicine from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. Morgan Stanley upgraded shares of Editas Medicine from an “underweight” rating to an “equal weight” rating and set a $7.00 price objective for the company in a report on Thursday, May 9th. Finally, Evercore ISI dropped their price target on shares of Editas Medicine from $15.00 to $7.00 and set an “in-line” rating on the stock in a report on Thursday, May 30th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $12.90.
Get Our Latest Analysis on EDIT
Editas Medicine Company Profile
Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Read More
- Five stocks we like better than Editas Medicine
- Dividend Capture Strategy: What You Need to Know
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Dividend Payout Ratio Calculator
- Why Call Options Volume for These 2 Stocks Spiked Together
- Top Stocks Investing in 5G Technology
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.